局部晚期直肠癌短程放疗后化疗或放化疗的生活质量与晚期毒性——RAPIDO试验
RAPIDO试验中局部晚期直肠癌患者随机接受短程放疗后术前化疗(EXP)或放化疗及可选术后化疗(STD),术后3年评估生活质量、肠道功能与晚期毒性。EXP组与STD组在QLQ-C30、QLQ-CR29及LARS评分无显著差异,EXP组感觉相关症状显著多于全部STD患者但与STD+组无显著差异;TNT不损害生活质量、肠道功能且不增加≥3级毒性。
要点
- EXP组与STD组在EORTC QLQ-C30、QLQ-CR29及LARS评分无显著差异。
- EXP组感觉相关症状显著多于全部STD患者,但与STD+组无显著差异。
- EXP组与STD组任何级别及≥3级毒性在所有时间点相当。
核心结论
- TNT用于局部晚期直肠癌可改善疾病相关治疗失败与病理完全缓解,且与标准放化疗相比在术后3年无DrTF患者中不损害健康相关生活质量、肠道功能或不增加≥3级毒性。
研究设计与样本
- RAPIDO试验随机分组:EXP组接受短程放疗后术前化疗,STD组接受放化疗及可选术后化疗。
- STD组分为接受(STD+)与未接受(STD-)术后化疗的患者。
- 术后3年发放EORTC QLQ-C30、QLQ-CR29、QLQ-CIPN20及LARS问卷。
- 574例合格患者中495例问卷返回(86%),453例纳入分析(79%在时限内完成)。
- 在毒性评估(6、12、24或36个月)前发生DrTF事件的患者被排除分析。
主要发现
- EXP组与STD组在QLQ-C30、QLQ-CR29或LARS评分无显著差异。
- 感觉相关症状在EXP组显著多于全部STD患者,但EXP组与STD+组无显著差异。
- EXP组与STD组任何级别毒性和≥3级毒性在所有时间点相当。
- 1-2级神经毒性在EXP组和STD+组所有时间点显著多于STD-组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The RAPIDO trial demonstrated a decrease in disease-related treatment failure (DrTF) and an increase in pathological complete responses (pCR) in locally advanced rectal cancer (LARC) patients receiving total neoadjuvant treatment (TNT) compared to conventional chemoradiotherapy. This study examines health-related quality of life (HRQL), bowel function, and late toxicity in patients in the trial. MATERIALS AND METHODS: Patients were randomized between short-course radiotherapy followed by pre-operative chemotherapy (EXP), or chemoradiotherapy and optional post-operative chemotherapy (STD). The STD group was divided into patients who did (STD+) and did not (STD-) receive post-operative chemotherapy. Three years after surgery patients received HRQL (EORTC QLQ-C30, QLQ-CR29 and QLQ-CIPN20) and LARS questionnaires. Patients who experienced a DrTF event before the toxicity assessments (6, 12, 24, or 36 months) were excluded from analyses. RESULTS: Of 574 eligible patients, 495 questionnaires were returned (86%) and 453 analyzed (79% completed within time limits). No significant differences were observed between the groups regarding QLQ-C30, QLQ-CR29 or LARS scores. Sensory-related symptoms occurred significantly more often in the EXP group compared to all STD patients, but not compared to STD+ patients. Any toxicity of any grade and grade ≥ 3 toxicity was comparable between the EXP and STD groups at all time-points. Neurotoxicity grade 1-2 occurred significantly more often in the EXP and STD+ group at all time-points compared to the STD- group. CONCLUSION: The results demonstrate that TNT for LARC, yielding improved DrTF and pCRs, does not compromise HRQL, bowel functional or results in more grade ≥3 toxicity compared to standard chemoradiotherapy at three years after surgery in DrTF-free patients.
引用
- Dijkstra EA, Hospers GAP, Kranenbarg EM, et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial. Radiother Oncol. 2022. PMID: 35447283. doi:10.1016/j.radonc.2022.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。